Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

In vitro evidence for a nonselective 4R tau PET tracer

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE. Small-molecule PET tracers for imaging proteinopathies. Semin Nucl Med. 2017;47:553–75.

    Article  Google Scholar 

  2. Goedert M, Yamaguchi Y, Mishra SK, Higuchi M, Sahara N. Tau filaments and the development of positron emission tomography tracers. Front Neurol. 2018;9:70

    Article  Google Scholar 

  3. Malarte ML, Gillberg PG, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol Psychiatry. 2022.

  4. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.

    Article  CAS  Google Scholar 

  5. Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408–19.

    Article  Google Scholar 

  6. Kroth H, Oden F, Molette J, Schieferstein H, Gabellieri E, Mueller A, et al. PI-2620 lead optimization highlights the importance of off-target assays to develop a PET tracer for the detection of pathological aggregated tau in Alzheimer’s disease and other tauopathies. J Med Chem. 2021;64:12808–30.

    Article  CAS  Google Scholar 

  7. Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547:185–90.

    Article  CAS  Google Scholar 

  8. Murugan NA, Nordberg A, Agren H. Different positron emission tomography tau tracers bind to multiple binding sites on the Tau fibril: insight from computational modeling. ACS Chem Neurosci. 2018;9:1757–67.

    Article  CAS  Google Scholar 

  9. Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimer’s Res Ther. 2017;9:96

    Article  CAS  Google Scholar 

  10. Williams DR. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J. 2006;36:652–60.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations



All contributions to this article including drafting and revising the manuscript were made by TJB.

Corresponding author

Correspondence to Tobey J. Betthauser.

Ethics declarations

Competing interests

TJB has received funding from the Alzheimer’s Association and the National Institute on Aging under the grants listed below but has no other relevant disclosures. NIH/NIA R01AG021155, RF1AG027161, R01AG062285, P30AG062715, R01AG070883 and the Alzheimer’s Association AARF-19-614533.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Betthauser, T.J. In vitro evidence for a nonselective 4R tau PET tracer. Mol Psychiatry (2023).

Download citation

  • Published:

  • DOI:


Quick links